Clinical update on a phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): The SHELTER study.
M. Bitzer
No relevant relationships to disclose
M. Horger
No relevant relationships to disclose
T. M. Ganten
No relevant relationships to disclose
M. P. Ebert
No relevant relationships to disclose
J. T. Siveke
No relevant relationships to disclose
M. A. Woerns
No relevant relationships to disclose
M. M. Dollinger
No relevant relationships to disclose
G. Gerken
No relevant relationships to disclose
M. E. Scheulen
No relevant relationships to disclose
A. Mais
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
R. Jankowsky
Employment or Leadership Position - 4SC
B. Hauns
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
B. Hentsch
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
U. M. Lauer
No relevant relationships to disclose